Capricor/$CAPR
1D1W1MYTD1Y5YMAX
Capital at risk
About Capricor
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
- Ticker
- $CAPR
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 231
- Headquarters
- San Diego, United States
- Website
- www.capricor.com
Capricor Metrics
BasicAdvanced
$498M
-
-$2.47
0.53
-
Price and volume
Market cap
$498M
Beta
0.53
52-week high
$40.37
52-week low
$2.96
Average daily volume
8.7M
Financial strength
Current ratio
7.346
Quick ratio
7.219
Long term debt to equity
0.364
Total debt to equity
0.37
Interest coverage (TTM)
-44.38%
Profitability
EBITDA (TTM)
-133.093
Effective tax rate (TTM)
-0.00%
Management effectiveness
Return on assets (TTM)
-33.63%
Return on equity (TTM)
-73.70%
Valuation
Price to book
2.02
Price to tangible book (TTM)
1.77
Price to free cash flow (TTM)
-3.462
Free cash flow yield (TTM)
-28.89%
Free cash flow per share (TTM)
-2.473
Growth
Earnings per share change (TTM)
48.91%
3-year earnings per share growth (CAGR)
28.33%
10-year earnings per share growth (CAGR)
-12.22%
What the Analysts think about Capricor
Analyst ratings (Buy, Hold, Sell) for Capricor stock.
Analyst projections of the future price of Capricor stock.
Bulls say / Bears say
CAPR.O shares jumped 116.9% to $9.13 premarket after the FDA agreed to review additional deramiocel data, signaling strong investor confidence in the therapy’s regulatory progress. (Reuters)
The FDA’s willingness to examine amended clinical data and extend the PDUFA deadline was called a “very unexpected and potentially positive” surprise by analysts, reducing near-term regulatory risk. (Reuters)
Cantor Fitzgerald analyst Kristen Kluska observed that the FDA’s openness to new muscle function data significantly cut regulatory uncertainty and improved the stock’s risk profile. (Reuters)
An FDA advisory committee voted nine-to-three against deramiocel’s effectiveness data, triggering a roughly 50% stock drop and highlighting serious concerns over efficacy. (Reuters)
Panel members cited unconvincing cardiac-benefit evidence, missing data and unclear patient impact, suggesting the Phase 3 endpoints may not demonstrate meaningful clinical benefit. (Reuters)
Last year’s Complete Response Letter for insufficient evidence, coupled with the negative panel vote, raises the probability of another CRL if the FDA does not find the new data compelling by the August 22 decision date. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 26 Aug 2026.
Capricor Financial Performance
Revenues and expenses
Capricor Earnings Performance
Company profitability
Upcoming events
No upcoming events
Capricor News
AllArticlesVideos
Faruqi & Faruqi, LLP Urges Capricor Therapeutics, Inc. (CAPR) Investors to Seek Counsel Before the September 28, 2026 Lead Plaintiff Deadline in the Securities Class Action
Newsfile Corp3 hours ago
CLASS ACTION DEADLINE APPROACHING: Berger Montague Advises Capricor Therapeutics, Inc. (CAPR) Investors to Inquire About a Securities Fraud Class Action by September 28, 2026
Newsfile Corp3 hours ago
CAPR Investor Reminder: Capricor Therapeutics Securities Fraud Class Action after 64% Stock Drop is Pending – Investors Notified to Contact BFA Law before September 28 Deadline
Business Wire7 hours ago
Funds containing Capricor
AllEURGBPUSD
Fund name | Fund size | $CAPR weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.02% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | €2.8B | 0.01% |
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | £2.4B | 0.01% |
SPDR MSCI All Country World IM€SPYI | €7.5B | 0.00% |
iShares MSCI World Small Cap$WSML | $9B | 0.00% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.